CE: Implementing Effective Protocols When Using Direct Oral Anticoagulant Reversal Agents: A Review of Updated Guidelines and Clinical Data

Pharmacy Times, October 2020, Volume 88, Issue 10

This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.

This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Examine the most current recommendations and guidelines for the use of FDA-approved direct oral anticoagulant (DOAC) reversal agents
  • Analyze the mechanisms of action, safety and efficacy data, and adverse effects associated with the use of approved DOAC reversal agents
  • Differentiate the recommended protocols for the preparation of the FDA-approved DOAC reversal agents
  • Explain the role of the health-system pharmacist in improving patient outcomes via clinical recommendations regarding the proper use of DOAC reversal agents and in anticoagulation monitoring protocols

FACULTY

Snehal H. Bhatt, PharmD, BCPS-AQ Cardiology, FASHP, AACC

Professor of Pharmacy Practice, MCPHS University; Boston, Massachusetts

TARGET AUDIENCE: Pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: October 15, 2020

EXPIRATION DATE: October 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.